Compare AbCellera Biologics Inc (ABCL) vs Amazon.com Inc (AMZN) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Amazon (AMZN) trades at $242.55, down 0.66% on the day, with a bullish technical outlook supported by moving averages. The company reported strong revenue growth to $716.92 billion in 2025, with net income reaching $77.67 billion and a profit margin of 10.83%. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS and AI chip capacity, driving positive sentiment. The stock is near key support at $243, with resistance at $248.

Outlook remains positive with 88.3% analyst buy ratings and a $321.11 consensus price target, implying significant upside. Risks include intense competition in e-commerce and cloud services, high valuation multiples, and macroeconomic pressures. Earnings growth and AI-driven AWS expansion are key catalysts, but investors should monitor execution and capex trends.